Literature DB >> 10444234

Arrhythmogenic mechanisms of non-sedating antihistamines.

Y G Yap1, A J Camm.   

Abstract

Antihistamines (H1-receptor antagonists) are amongst the most frequently prescribed drugs worldwide for the treatment of allergic conditions. Recently, there have been reports that certain non-sedating antihistamines, mainly terfenadine and astemizole, might be associated with the risk of rare but severe arrhythmias, namely torsades de pointes, particularly in overdosage, concomitant ingestion of imidazole or macrolide antibiotics and in patients with underlying cardiac or liver diseases. It has now been shown that the molecular target in human ventricle for the potassium channel blockade of antihistamine is HERG gene located in chromosome 7 that expresses the delayed rectifier IKr and appears to be involved in the congenital long QT syndrome. Mechanistic studies showed that blockade of IKr channels by these drugs leads to prolongation of the monophasic action potential (QT interval on surface electrocardiogram) which may then induce the development of early after-depolarization and dispersion of repolarisation leading to torsades de pointes through re-entry mechanism. There are still many questions that need to be answered such as the roles of other potassium channels (IKs, Ito, and Iped) and the relative expression of various potassium channels in different individuals which may be important in the pathogenesis of torsades de pointes with non-sedating antihistamines. There is also a lack of information on the cardiac actions of newer non-sedating antihistamines. It is hoped that with a better understanding of the arrhythmogenic mechanism of non-sedating antihistamines, one will be able to identify those at risk patients and prevent any cardiac toxicity associated with antihistamines and ultimately death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444234     DOI: 10.1046/j.1365-2222.1999.0290s3174.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  15 in total

1.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

Review 3.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 4.  Drug-induced arrhythmia: pharmacogenomic prescribing?

Authors:  Elijah R Behr; Dan Roden
Journal:  Eur Heart J       Date:  2012-10-22       Impact factor: 29.983

Review 5.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.

Authors:  Jiesheng Kang; David R Compton; Roy J Vaz; David Rampe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-16       Impact factor: 3.000

7.  Lack of clinically relevant interaction between desloratadine and erythromycin.

Authors:  Christopher Banfield; Thomas Hunt; Larisa Reyderman; Paul Statkevich; Desmond Padhi; Melton Affrime
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.

Authors:  Christopher Banfield; Jerry Herron; Anther Keung; Desmond Padhi; Melton Affrime
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

Authors:  Nenad Sarapa; Joel Morganroth; Jean-Philippe Couderc; Steven F Francom; Borje Darpo; Joseph C Fleishaker; Janet D McEnroe; William T Chen; Wojciech Zareba; Arthur J Moss
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.